Using proliferative markers and oncotype DX in therapeutic decision-making for breast cancer: The B. C. experience

Current Oncology

Volumn 22, Issue 3, 2015, Pages 192-198

  Baxter, E ^a   Gondara, L ^a   Lohrisch, C ^a   Chia, S ^a   Gelmon, K ^a   Hayes, M ^a   Davidson, A ^a   Tyldesley, Scott ^a  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

Breast cancer; Proliferative markers

Indexed keywords

BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR;

ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER STAGING; CORRELATION ANALYSIS; CORRELATION COEFFICIENT; DECISION MAKING; DIAGNOSTIC TEST; FEMALE; HEALTH SURVEY; HUMAN; KI-67 INDEX; LYMPH VESSEL METASTASIS; MITOTIC COUNT; NOTTINGHAM GRADE; ONCOTYPE DX; RECURRENCE SCORE; SCORING SYSTEM;

EID: 84931314295     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.22.2284     Document Type: Article

References (15)

1. Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006;24:3726–34.
2. Zybtek B, Cohen C, Wang J, Page A, Williams DJ, Adams AL. Nottingham-defined mitotic score: comparison with visual and image cytometric phosphohistone H3 labeling indices and correlation with Oncotype dx Recurrence Score. Appl Immunohistochem Mol Morphol 2013;21:48–53.
3. Dowsett M, Nielsen TO, A’Hern R, et al. Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer Working Group. J Natl Cancer Inst 2011;103:1656–64.
4. Inwald EC, Klinkhammer-Schalke M, Hofstädter F, et al. Ki-67 is a prognostic parameter in breast cancer patients: results of a large population-based cohort of a cancer registry. Breast Cancer Res Treat 2013;139:539–52.
5. Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thürlimann B, Senn HJ. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol 2009;20:1319–29.
6. Cheang MC, Chia SK, Voduc D, et al. Ki67 index, her2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 2009;101:736–50.
7. de Azambuja E, Cardoso F, de Castro G Jr, et al. Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients. Br J Cancer 2007;96:1504–13.
8. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004;351:2817–26.
9. Zujewski JA, Kamin L. Trial assessing individualized options for treatment for breast cancer. The tailorx trial. Future Oncol 2008;4:603–10.
10. Davidson JA, Cromwell I, Ellard SL, et al. A prospective clinical utility and pharmacoeconomic study of the impact of the 21-gene Recurrence Score assay in oestrogen receptor positive node negative breast cancer. Eur J Cancer 2013;49:2469–75.
11. Dancey CP, Reidy J. Statistics Without Maths for Psychology. 5th ed. Harlow, UK: Pearson Education; 2011.
12. Cohen J. A coefficient of agreement for nominal scales. Educ Psychol Meas 1960;20:37–46.
13. Auerbach J, Kim M, Fineberg S. Can features evaluated in the routine pathologic assessment of lymph node-negative estrogen receptor-positive stage i or ii invasive breast cancer be used to predict the Oncotype dx Recurrence Score? Arch Pathol Lab Med 2010;134:1697–701.
14. Allison KH, Kandalaft PL, Sitlani CM, Dintzis SM, Gown AM. Routine pathologic parameters can predict Oncotype dx recurrence scores in subsets of er positive patients: who does not always need testing? Breast Cancer Res Treat 2012;131:413–24.
15. Flanagan MB, Dabbs DJ, Brufsky AM, Beriwal S, Bhargava R. Histopathologic variables predict Oncotype dx Recurrence Score. Mod Pathol 2008;21:1255–61.